The first randomized trial to test whether adding a small, temporary pump to allow the heart to rest and intentionally ...
HRS-1893 (also known as BHB-1893) is a selective, small-molecule, cardiac myosin inhibitor engineered to improve heart performance in patients with HCM. By modulating cardiac contractility, HRS-1893 ...
MedPage Today on MSN
Mavacamten poised to expand to pediatric obstructive hypertrophic cardiomyopathy
The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...
In stabilized heart attack survivors without heart failure or left ventricular (LV) systolic dysfunction, stopping the ...
The first randomized trial to compare standard percutaneous coronary intervention (PCI), also known as coronary angioplasty, with PCI accompanied by the use of a temporary, miniaturized pump to ...
CHICAGO, IL — AUGMENT HF, a phase 2 trial of 78 patients with advanced heart failure, showed that an injection of the novel hydrogel Algisyl-LVR hydrogel (LoneStar Heart, Dallas, TX) into their left ...
Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant ...
The role of long-term beta-blocker therapy after a myocardial infarction in patients without left ventricular systolic dysfunction or heart failure is unclear in the era of contemporary ...
During embryonic development, the right ventricle is formed from the secondary heart field into a crescent-shaped, thin-walled structure. 6 It is the most anterior heart chamber, sitting just beneath ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results